

June 27, 2017



## Viveve Selected for Inclusion in Russell 2000(R) Index

SUNNYVALE, CA -- (Marketwired) -- 06/27/17 -- Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that the company is positioned for inclusion in the Russell 2000 Index following reconstitution of Russell Indexes announced on June 26, 2017. Viveve Medical will be officially listed on the Index when markets open on Tuesday, June 27, 2017.

Patricia Scheller, chief executive officer of Viveve, commented, "In recent years awareness of the unmet need in women's health and wellness has continued to expand among healthcare providers, patients and investors. The addition of Viveve to the Russell 2000 Index is another validation of our continued growth and leadership in this area and of the global commercial opportunity with our landmark technology."

Membership in the small-cap Russell 2000<sup>®</sup> Index means automatic inclusion in the Russell 3000<sup>®</sup> Index as well as in the appropriate growth and value style indexes. The Russell 3000<sup>®</sup> Index encompasses the 3,000 largest U.S.-traded stocks by objective, market-capitalization rankings and style attributes. This weighted index by market capitalization was constructed to provide a comprehensive barometer of the broad market and it now represents approximately 98 percent of the investable U.S. equity market. The Russell Global Indexes reflect the performance of over 10,000 securities in 47 countries. Membership in these indexes is updated annually and remains in place for one year.

### **About Viveve**

Viveve Medical, Inc. is a women's health and wellness company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve<sup>®</sup> System, that delivers the GENEVEVE<sup>™</sup> treatment, incorporates cryogen-cooled, monopolar radiofrequency (CMRF) to uniformly deliver volumetric heating while gently cooling surface tissue to generate robust neocollagenesis in one 30-minute in-office session.

In the United States, the Viveve System is cleared by the FDA for general surgical procedures for electrocoagulation and hemostasis. Consistent with approvals in many countries internationally, Viveve is currently in the process of submitting an IDE to the FDA to conduct a pivotal study on use of the device in the United States for improvement in sexual function. For more information visit Viveve's website at [www.viveve.com](http://www.viveve.com).

### **Safe Harbor Statement**

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely

on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at [www.sec.gov](http://www.sec.gov). Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

*Viveve is a registered trademark of Viveve, Inc.  
Geneveve is a trademark of Viveve, Inc.*

Investor Relations contact:  
Amato and Partners, LLC  
90 Park Avenue, 17th Floor  
New York, NY 10016  
(212) 430-0360  
[admin@amatoandpartners.com](mailto:admin@amatoandpartners.com)

Media contact:  
Sara Zelkovic  
Berry & Company Public Relations  
(212) 253-8881  
[szelkovic@berrypr.com](mailto:szelkovic@berrypr.com)

Source: Viveve Medical, Inc.